4-Androstenediol
Names | |
---|---|
IUPAC name
(3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol | |
Other names
Androst-4-ene-3β,17β-diol | |
Identifiers | |
1156-92-9 | |
ChEMBL | ChEMBL195836 |
ChemSpider | 120071 |
DrugBank | DB01526 |
Jmol interactive 3D | Image Image |
PubChem | 136297 |
| |
| |
Properties | |
C19H30O2 | |
Molar mass | 290.44 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
Δ4-Androstenediol is an androstenediol that is converted to testosterone. The conversion rate is about 15.76%, almost triple that of Δ4-androstenedione, due to utilization of a different enzymatic pathway. There is also some conversion into estrogen, since testosterone is the metabolic precursor of the estrogens.
Δ4-Androstenediol is closer to testosterone structurally than Δ5-androstenediol, and has androgenic effects, acting as a weak partial agonist of the androgen receptor.[1] However, due to its lower intrinsic activity in comparison, in the presence of full agonists like testosterone or dihydrotestosterone (DHT), Δ4-androstenediol has antagonistic actions, behaving more like an antiandrogen.[1]
Medical and commercial use
Patrick Arnold holds a 1999 patent on "Use of 4-androstenediol to increase testosterone levels in humans".[2]
References
- 1 2 Chen F, Knecht K, Leu C; et al. (August 2004). "Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol". The Journal of Steroid Biochemistry and Molecular Biology 91 (4-5): 247–57. doi:10.1016/j.jsbmb.2004.04.009. PMID 15336702.
- ↑ http://www.patentstorm.us/patents/5880117/description.html
|